search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • News
  • News & Events
  • News
  • Immunologist Daniela Thommen wins Pfizer Science Award

Immunologist Daniela Thommen wins Pfizer Science Award

12-02-2019

On 7 February, Daniela Thommen, senior postdoc in the Schumacher lab, has been awarded a Pfizer Forschungspreis for her innovative  Nature Medicine paper, published in June 2018, about so-called exhausted T cells which turned out not to be so exhausted after all. 

Immunologist Daniela Thommen wins Pfizer Science Award

The Pfizer Forschungspreis is a prestigious Swiss science prize for young researchers who perform fundamental or clinical research in the field of health and medicine. Daniela won the award within the category of Oncology/ Basic Research, together with her co-authors Viktor H. Kölzer and Kirsten D. Mertz from the Cantonal Hospital Baselland.

 

The Research: Re-thinking T cell exhaustion - a potential Biomarker for Immunotherapy?

The aim was to assess whether heterogeneity in intratumoral dysfunctional T cells can be used as a personalized predictor of immunotherapy response in lung cancer. 

The recent success of cancer immunotherapy has significantly improved clinical outcome for a spectrum of cancer types. Different T cell populations play an important role but not all dysfunctional T cell populations may respond equally well to therapies like PD-1/PD-L1 blockade.

 

Highly exhausted T cells acquire novel function

The researchers performed molecular and functional analyses of distinct intratumoral T cell subsets from human lung carcinomas. They identified so-called PD-1T T cells (T cells with high PD-1 expression level) as a separate, highly tumor-reactive T cell population with a distinct transcriptional state. In addition, the researchers identified a novel function of those highly exhausted cells which they acquire at the tumor site. Most importantly, the researchers observed that the presence of PD-1T T cells correlates with a better response to anti-PD-1/PD-L1 therapy.

 

New biomarker for response to anti-PD-1/PD-L1 therapy?

The development of a digital imaging protocol for quantification of PD-1T T cells allows to translate these findings into a clinically applicable assay for human tissue samples. This assay will allow the validation of PD-1T T cells as a novel biomarker for response to anti-PD-1/PD-L1 therapy in larger patient cohorts. 

Daniela Thommen et al.,  A transcriptionally and functionally distinct PD-1+CD8+T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

Read more about the award (in German):

  • Pfizer Forschungspreis
  • De winnaars van 2019
  • Sind T-cellen wirklich Müde?

 

Daniela Thommen group Other tumors

Support our science?

Learn more

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.